Esperion Therapeutics to Present at BioCentury Newsmakers in the Biotech Industry Conference
September 24 2013 - 8:00AM
Business Wire
Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage
biopharmaceutical company focused on developing and commercializing
first-in-class, oral, low-density lipoprotein cholesterol (LDL-C)
lowering therapies for the treatment of hypercholesterolemia, today
announced that Tim M. Mayleben, Esperionâs president and chief
executive officer, will present at the BioCentury Newsmakers in the
Biotech Industry Conference in New York. Mr. Maylebenâs
presentation will take place on Friday, September 27 at 2:00 ET at
the Millennium Broadway Hotel and Conference Center.
To hear the live audio webcast and view the slides of the
Esperion presentation, please visit
(http://www.visualwebcaster.com/event.asp?id=95799). A replay of
the webcast will be available on the companyâs website for 90
days following the live event.
About Esperion Therapeutics
Esperion Therapeutics, Inc. is a biopharmaceutical company
focused on the research, development and commercialization of
therapies for the treatment of patients with elevated levels of
low-density lipoprotein cholesterol (LDL-C) and other
cardiometabolic risk factors. ETC-1002, Esperion's lead product
candidate, is a unique, first-in-class, orally available,
once-daily small molecule designed to lower levels of LDL-C and to
avoid side effects associated with existing LDL-C lowering
therapies. ETC-1002 is targeted for statin intolerant patients with
elevated levels of LDL-C. Esperion has completed seven clinical
studies to date, including four Phase 2a studies, and expects to
initiate a robust Phase 2b clinical program in the fourth quarter
of 2013. For more information, please visit www.esperion.com.
BrewLifeDenise Powell, 510-703-9491dpowell@brewlife.com
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jul 2023 to Jul 2024